Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bilastine - FAES Farma

Drug Profile

Bilastine - FAES Farma

Alternative Names: Aligrin; Bellozal; Bilador; Bilahist; Bilanoa; Bilaska; Bilaxten; Bilaz; Bilidren; BLEXTEN; Borenar; Clatra; Drynol; F-96221-BM; Fortecal; Gosall; Ibis; Ilaxten; Inorial; Labixten; Lamiastine; Lendin; Lergonix; Nasitop; Nixar; Obalix; Olisir; Omarit; Opexa; Revitelle; Robilas; TAC-202; Vitador; Xados; Zilas

Latest Information Update: 03 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FAES Farma
  • Developer Aralez Pharmaceuticals Inc.; FAES Farma; Menarini; Menarini Asia-Pacific; Taiho Pharmaceutical; Yuhan
  • Class Antiallergics; Antihistamines; Benzimidazoles; Eye disorder therapies; Piperidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis; Urticaria
  • Phase III Allergic rhinoconjunctivitis
  • Phase I Unspecified
  • Discontinued Angioedema

Most Recent Events

  • 31 Dec 2018 Nuvo Pharmaceuticals in-licenses Bilastine from Aralez Pharmaceuticals
  • 26 Sep 2018 Phase-III clinical trials in Allergic conjunctivitis in Lithuania (Ophthalmic) (EudraCT2018-002248-95)
  • 19 Sep 2018 Nuvo Pharmaceuticals and Aralez Pharmaceuticals enter into a purchase agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top